Althera Pharmaceuticals LLC – Trademark Portfolio

Entity Type: 16

Althera Pharmaceuticals LLC holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ROSZET. The owner is based in Morristown, NJ.

STE 1448, IP Legal

89 Headquarters Plaza, STE 1448

Morristown, NJ 07960

6 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

LYPQOZET
LYPQOZET
Abandoned 2020
LIPPEZET
LIPPEZET
Abandoned 2020
ATORZET
ATORZET
Abandoned 2020
ATOREZE
ATOREZE
Abandoned 2020
ROSZET
ROSZET
Registered 2019
ROSTUZET
ROSTUZET
Abandoned 2019

Trademark Classifications

Althera Pharmaceuticals LLC's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (6 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Althera Pharmaceuticals LLC have?

Althera Pharmaceuticals LLC has 6 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 abandoned.

What trademark classes does Althera Pharmaceuticals LLC file in?

Althera Pharmaceuticals LLC files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Althera Pharmaceuticals LLC's most well-known trademarks?

Althera Pharmaceuticals LLC's registered trademark portfolio includes well-known marks such as ROSZET. These are among 1 currently registered trademark in the portfolio.

What is Althera Pharmaceuticals LLC's trademark registration success rate?

Althera Pharmaceuticals LLC has a 17% trademark registration rate, with 1 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.